Loading…
Bristol-Myers Squibb Company is projected to rise to $66.70 by 2027, a +16% move from its current price of $57.58. BMY is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $56.72 | $57.59 | $58.47 | +0.01% |
| Jul 15 | $56.37 | $57.60 | $58.84 | +0.03% |
| Jul 16 | $56.11 | $57.60 | $59.14 | +0.04% |
| Jul 17 | $55.89 | $57.61 | $59.39 | +0.05% |
| Jul 18 | $55.70 | $57.62 | $59.61 | +0.07% |
| Jul 19 | $55.52 | $57.63 | $59.81 | +0.08% |
| Jul 20 | $55.36 | $57.63 | $59.99 | +0.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $55.36 | $57.63 | $59.99 | +0.09% |
| Week 2 | $54.50 | $57.69 | $61.06 | +0.18% |
| Week 3 | $53.86 | $57.74 | $61.90 | +0.27% |
| Week 4 | $53.33 | $57.79 | $62.62 | +0.37% |
| Week 5 | $52.88 | $57.84 | $63.28 | +0.46% |
| Week 6 | $52.47 | $57.90 | $63.88 | +0.55% |
| Week 7 | $52.11 | $57.95 | $64.45 | +0.64% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bristol-Myers Squibb Company is a healthcare company that discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. It was founded in 1887 and is headquartered in Princeton, New Jersey.
Bristol-Myers Squibb Company (BMY) is a healthcare stock with a current price of $58.56 and a market capitalization of $119.58B, ranking 124 by market cap. The stock trades in a broad market with a diverse portfolio of biopharmaceutical products across multiple therapeutic areas.
A major floor 9.4% below — a decisive break under it would weaken the trend.
The nearest floor, 6.2% below — buyers have tended to step in here.
Price is pressing into resistance (1.7% away) — a breakout level to watch.
A major ceiling 8.2% above — clearing it would confirm fresh momentum.
Key BMY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BMY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $57.55 | Buy | $57.60 | Sell |
| MA 10 | $57.60 | Sell | $57.32 | Buy |
| MA 20 | $56.60 | Buy | $56.97 | Buy |
| MA 50 | $56.85 | Buy | $57.04 | Buy |
| MA 100 | $58.23 | Sell | $56.82 | Buy |
| MA 200 | $54.32 | Buy | $55.36 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.87 | Neutral |
| Stoch RSI (14) | 62.49 | Neutral |
| CCI (20) | 59.44 | Neutral |
| Williams %R (14) | -25.39 | Info |
| MACD (12,26,9) | 0.20 | Buy |
| ROC (12) | 3.69 | Buy |
| Bollinger %B (20,2) | 0.69 | Neutral |
| Stochastic %K (14) | 74.61 | Neutral |
| TRIX (15) | 0.02 | Buy |
| Awesome (5,34) | 0.89 | Buy |
| Ultimate (7,14,28) | 53.78 | Neutral |
| Momentum (10) | 2.19 | Buy |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 57.80 | Sell |
| ADX (14) | 9.46 | Neutral |
| ATR (14) | 0.89 | Info |
The 30-day technical picture shows a bullish stance with RSI14 at 60 and price action hovering near key moving averages. The SMA50 is $57.08, and the SMA200 is $53.86, indicating near-term support around recent levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $53.06 | $57.58 | $71.59 | 0% | Neutral | |
| $54.63 | $66.70 | $85.14 | +16% | Neutral | |
| $57.84 | $71.94 | $94.31 | +25% | Bullish | |
| $58.95 | $74.45 | $99.69 | +29% | Bullish | |
| $66.72 | $85.41 | $116.42 | +48% | Bullish | |
| $75.75 | $98.15 | $135.90 | +70% | Bullish | |
| $85.24 | $111.70 | $156.85 | +94% | Bullish | |
| $92.97 | $123.11 | $175.12 | +114% | Bullish | |
| $91.42 | $122.26 | $175.99 | +112% | Bullish | |
| $95.21 | $128.53 | $187.08 | +123% | Bullish | |
| $140.49 | $197.83 | $301.75 | +244% | Bullish | |
| $257.21 | $388.44 | $635.11 | +575% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $53.06 | $57.58 | $68.57 | +0.00% |
| August 2026 | $49.26 | $57.65 | $68.92 | +0.13% |
| September 2026 | $49.55 | $58.27 | $70.21 | +1.07% |
| October 2026 | $50.47 | $59.59 | $72.28 | +2.27% |
| November 2026 | $49.94 | $59.17 | $72.17 | -0.71% |
| December 2026 | $49.13 | $58.40 | $71.59 | -1.30% |
Click any year to see its month-by-month BMY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BMY is projected to trade between $53.06 and $71.59, averaging $57.58 — a potential gain of 0% from today's $57.58. A consolidation phase looks the most probable path here.
Bristol-Myers Squibb Company's 2027 outlook centres on $66.70, within a $54.63 to $85.14 range. That is up +16% on the projected 2026 average. That marks a +16% change versus current levels. Price action looks broadly range-bound.
By 2028, BMY could reach as high as $94.31, with a base case around $71.94 and support toward $57.84 — roughly +25% from $57.58. Buyers look set to stay in control over this stretch.
Expect BMY to range from $58.95 to $99.69 through 2029. The $74.45 average target implies a +29% move from current prices. That is up +3% on the projected 2028 average. Momentum favours further upside here.
The BMY price prediction for 2030 points to an average of $85.41 (low $66.72, high $116.42) — a potential gain of +48% on today's $57.58. Buyers look set to stay in control over this stretch.
In 2031, BMY is projected to trade between $75.75 and $135.90, averaging $98.15 — a potential gain of +70% from today's $57.58. That is up +15% on the projected 2030 average. Momentum favours further upside here.
Bristol-Myers Squibb Company's 2032 outlook centres on $111.70, within a $85.24 to $156.85 range. That is up +14% on the projected 2031 average. That marks a +94% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, BMY could reach as high as $175.12, with a base case around $123.11 and support toward $92.97 — roughly +114% from $57.58. Momentum favours further upside here.
Expect BMY to range from $91.42 to $175.99 through 2034. The $122.26 average target implies a +112% move from current prices. That is -1% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The BMY price prediction for 2035 points to an average of $128.53 (low $95.21, high $187.08) — a potential gain of +123% on today's $57.58. Momentum favours further upside here.
In 2040, BMY is projected to trade between $140.49 and $301.75, averaging $197.83 — a potential gain of +244% from today's $57.58. That is up +54% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Bristol-Myers Squibb Company's 2050 outlook centres on $388.44, within a $257.21 to $635.11 range. That is up +96% on the projected 2040 average. That marks a +575% change versus current levels. Momentum favours further upside here.
Investing $1,000 in BMY today (≈ 17.367141 BMY) could be worth
$6,746.02
+$5,746.02 (+575%) by 2050 · US Dollar
Based on the average projected BMY price of $388.44 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BMYwould be worth at today's price.
$1,000 invested in BMY on Jul 10, 2025 (≈ 20.610058 BMY) would be worth
$1,186.73
+$186.73 (+18.7%) today · 1.19× · US Dollar
Based on a BMY entry price of $48.52 vs. today's $57.58.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $58.13 | $990.54 | -0.9% |
| 1 month ago | $55.6 | $1,035.61 | +3.6% |
| 3 months ago | $58.62 | $982.26 | -1.8% |
| 6 months ago | $55.77 | $1,032.45 | +3.2% |
| 1 year ago | $48.52 | $1,186.73 | +18.7% |
| All time (5.0y) ago | $67.88 | $848.26 | -15.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BMY forecast.
Our base-case forecast reaches $120.00 around 2033.
Implied market cap at $120.00: $245.05B
The multi-year forecast shows a steady uptrend in average prices with bullish sentiment from 2028 onward. In 2030 the average price is projected at $90.14, with a min of $70.38 and a max of $122.93, and a return on investment of 53.9%. By 2040, the average price is projected at $211.12 (min $149.89, max $322.12) with an ROI of 260.5%.
By 2050, the average price is projected at $425.09 (min $281.42, max $695.19) with an ROI of 625.9%. The longer horizon remains bullish across these milestones.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $90.14, a minimum of $70.38, and a maximum of $122.93, with an ROI of 53.9% and a bullish sentiment.
The forecast outlines rising averages and positive ROIs after 2026, with a 2030 average of $90.14 and a 2050 average of $425.09, corresponding to an ROI of up to 625.9%. The long-term outlook is bullish, though these are estimates, not guarantees.
Yes. The forecast shows a 2031 average of $103.42 with a maximum of $143.27, and a 2030 maximum of $122.93, indicating prices could exceed $100 in the forecast horizon.
The current price is $58.56.
For 2040, the average price is projected at $211.12, with a minimum of $149.89 and a maximum of $322.12, and an ROI of 260.5%, with a bullish sentiment.
Bristol-Myers Squibb Company Community Discussion
0Share your Bristol-Myers Squibb Company price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.